<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341286</url>
  </required_header>
  <id_info>
    <org_study_id>TK3b FII ABC</org_study_id>
    <nct_id>NCT03341286</nct_id>
  </id_info>
  <brief_title>The Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.</brief_title>
  <acronym>TK3bFIIABC</acronym>
  <official_title>Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The product under investigation relates to a pharmaceutical composition containing a
      pyrimidine nitrogen base, thymine, and the essential amino acid tryptophan. This product
      seems to have effect on quality of life and enhance adverse affects of chemotherapy in cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the impact of TK3 on the quality of life
      of patients receiving anti-neoplastic chemotherapy. The secondary objectives are to evaluate
      the influence of TK3 on the side effects caused by anti-neoplastic chemotherapy, tolerance to
      this treatment and the safety of the use of the TK3 product in cancer patients, accompanying
      the appearance of non-characteristic effects of the existing cancer type .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The role of TK3 in the quality of life of patients receiving anti-neoplastic chemotherapy after 3 cicles of chemotherapy</measure>
    <time_frame>It depends on the chemotherapy schedule: 14 or 21 days</time_frame>
    <description>use of quality of life questionaire QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of TK3 in the quality of life of patients receiving anti-neoplastic chemotherapy after 3 cicles of chemotherapy</measure>
    <time_frame>It depends on the chemotherapy schedule: 14 or 21 days</time_frame>
    <description>use of quality of life questionaire FACIT-F</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effects of TK3 on tolerance to anti-neoplastic chemotherapy, with emphasis on the most prevalent side effects, especially fatigue related to cancer treatment according to CTCAE scale of adverse events v 4.0</measure>
    <time_frame>It depends on the chemotherapy schedule: 14 or 21 days</time_frame>
    <description>use of CTCAE scale of adverse events v 4.0 and Edmonton scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drugs safety according to CTCAE scale of adverse events v 4.0</measure>
    <time_frame>It depends on the chemotherapy schedule: 14 or 21 days</time_frame>
    <description>safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Tryptophan</condition>
  <condition>Thiamine</condition>
  <arm_group>
    <arm_group_label>TK3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally, to be taken three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TK3</intervention_name>
    <description>Tryptophan and thiamine as on oral supplement</description>
    <arm_group_label>TK3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who agree to study procedures and sign the informed consent

          -  Patients 18 years of age or older;

          -  Patients undergoing oncologic treatment for advanced neoplasms. It is understood by
             advanced patient disease patients with unresectable or with distant metastases.

          -  Participants should present at least one (1) of the following clinical side effects
             that can be assessed according to CTCAE (Version 4.0): fatigue, nausea, vomiting,
             diarrhea, or mucositis.

          -  Patients with programming to receive at least 3 cycles of anti-neoplastic
             chemotherapy;

          -  Patients may be on radiotherapy

        Exclusion Criteria:

          -  Use of vitamin complex or concomitant food supplement;

          -  Current use or programming of parenteral diet use;

          -  Hypersensitivity to the components of the formula;

          -  Participation in another clinical study or use of any investigational product within
             28 days prior to commencement of treatment in this clinical trial, unless the
             Investigator deems there to be a clinical benefit therefore;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculdade de medicina do ABC-CEPHO</name>
      <address>
        <city>Santo Andr√©</city>
        <state>SP</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andressa Tamashiro</last_name>
      <phone>+551149935491</phone>
      <email>andressa@cepho.org.br</email>
    </contact>
    <investigator>
      <last_name>Daniel IG Cubero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia VM Sette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline APR Lima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Auro Del giglio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Butt Z, Lai JS, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale. J Psychosom Res. 2013 Jan;74(1):64-8. doi: 10.1016/j.jpsychores.2012.10.011. Epub 2012 Nov 15.</citation>
    <PMID>23272990</PMID>
  </reference>
  <reference>
    <citation>Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage. 2011 Feb;41(2):456-68. doi: 10.1016/j.jpainsymman.2010.04.020. Epub 2010 Sep 15.</citation>
    <PMID>20832987</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991 Summer;7(2):6-9.</citation>
    <PMID>1714502</PMID>
  </reference>
  <reference>
    <citation>Monteiro Dda R, Almeida Mde A, Kruse MH. [Translation and cross-cultural adaptation of the Edmonton Symptom Assessment System for use in Palliative Care]. Rev Gaucha Enferm. 2013 Jun;34(2):163-71. Portuguese.</citation>
    <PMID>24015476</PMID>
  </reference>
  <reference>
    <citation>Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011 Jan 1;29(1):89-96. doi: 10.1200/JCO.2010.28.0107. Epub 2010 Nov 22. Review.</citation>
    <PMID>21098316</PMID>
  </reference>
  <reference>
    <citation>Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002 Jul 15;20(14):3106-13.</citation>
    <PMID>12118024</PMID>
  </reference>
  <reference>
    <citation>Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015 Dec;154(3):509-20. doi: 10.1007/s10549-015-3633-7. Epub 2015 Nov 14.</citation>
    <PMID>26567010</PMID>
  </reference>
  <reference>
    <citation>Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res. 2009 Sep;18(7):853-61. doi: 10.1007/s11136-009-9493-z. Epub 2009 Jul 1.</citation>
    <PMID>19568958</PMID>
  </reference>
  <reference>
    <citation>Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol. 2005 Oct 20;23(30):7417-27. Epub 2005 Sep 12.</citation>
    <PMID>16157935</PMID>
  </reference>
  <reference>
    <citation>Southwest Oncology Group, Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20;24(18):2828-35.</citation>
    <PMID>16782921</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Daniel de Iracema Gomes Cubero</investigator_full_name>
    <investigator_title>PHD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

